MTHFR-1298 AC is a predictor of survival in two cohorts of stage II/III colorectal cancer patients t...
MTHFR-1298 AC is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin
About this item
Full title
Author / Creator
Cecchin, E , Perrone, G , Nobili, S , Polesel, J , De Mattia, E , Zanusso, C , Petreni, P , Lonardi, S , Pella, N , D'Andrea, M , Errante, D , Rizzolio, F , Mazzei, T , Landini, I , Mini, E and Toffoli, G
Publisher
Nature Publishing Group
Journal title
Language
English
Formats
Publication information
Publisher
Nature Publishing Group
Subjects
More information
Scope and Contents
Contents
Adjuvant treatment based on fluoropyrimidines (FL) Improves the prognosis of stage II/III colorectal cancer (CRC). Validated predlctlve/prognostlc biomarkers would spare therapy-related morbidity in patients with a good prognosis. We compared the impact of a set of 22 FL-related polymorphisms with the prognosis of two cohorts of CRC patients treate...
Alternative Titles
Full title
MTHFR-1298 AC is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracmisc_A416596529
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A416596529
Other Identifiers
ISSN
1470-269X
DOI
10.1038/tpj.2014.64
